For how we live.
In 216 patients with chronic patellofemoral pain across 10 Korean hospitals, an 8-week digital therapeutic beat education and exercise instruction on pain — by 12.5 mm on a 100 mm scale.
In 6,772 users of a US health system's AI triage tool, people engaged about twice as often when the AI matched what they already planned — raising a hard question about what the tools are steering.
A review of 41 studies found that the great majority of AI medication-adherence prediction models carried high risk of bias, and that fancier algorithms did not reliably predict better.
Thirty-two interviews across Uruguay, Argentina, Chile and Mexico find implementation turned on governance, not software. A separate patent analysis shows where digital therapeutics are not being built.
Eye strain is close to universal among heavy device users, and it is temporary. The evidence that screen time causes myopia is real but weak, and every study of it measured screen time by questionnaire.
In a 22,785-user study of one temperature-based app, typical use failed 6.9 per 100 woman-years and perfect use 1.0 — but the study came from the maker, and traditional methods vary widely.
A review of Paige Prostate Detect and Ibex Prostate Detect finds the tools mainly help less-specialized pathologists, and warns performance shifts when a tool meets a new population.
A meta-analysis of fully automated programmes found a large effect on insomnia severity. A review of 68 studies found the field has barely measured whether recipients find them acceptable.
A cross-sectional analysis of NICE evaluations found 78 supporting studies behind 30 technologies — and consistent holes in comparators, cost of delivery and adverse-event reporting.
A Nature Communications review of the continent's biomedical data science capacity found none of 36 surveyed groups using cloud high-performance computing, and named electricity outages among the most common obstacles.
A 1,298-person randomized study found people using chatbots to work through medical scenarios did no better than people without them — even though the same chatbots, tested alone, got the right answer most of the time.
Researchers ran 960 responses through ChatGPT Health using clinician-written vignettes. Failures clustered at both extremes, and crisis safeguards activated unpredictably.
A small qualitative study finds device dependency, blurred motivation and users who no longer trust their own bodies. It lands as health services keep integrating the same devices.
A 250-person randomised trial paired a wearable tracker with just-in-time energy-management messages. Post-exertional malaise fell in both arms, and the difference between them was trivial.
A trial across five Chinese hospitals found remote robotic urological surgery non-inferior to local surgery. The sample is small, the surgeons were experts, and the network never failed.
Clinicians rated empathy at 4.6 out of 5 and quality of information at 2.7. Every chatbot produced at least one piece of guidance judged inappropriate, overstated or inaccurate.
The FDA's revised general wellness policy lets non-invasive devices infer blood pressure, glucose and other physiologic parameters. The regulated line is no longer the measurement — it is the sentence next to it.
Standard questionnaires found no daytime difference between suvorexant and placebo. Four-times-daily smartphone prompts found fatigue worse in the morning and better later. The trial had 40 people.
A mirror that scores physiological age in 30 seconds. A watch that watches your gait for dementia. The gap between what these products measure and what they imply is the story of the show.
The headline finding is noninferiority. The more useful finding is what the shared denominator was — and how wide a gap the trial was designed to tolerate.
PpgAge predicts chronological age from consumer wearable photoplethysmography and tracks disease. The same optical method has documented accuracy problems across skin tones.
Google's PH-LLM beat sampled human experts on multiple-choice tests but only matched them on real cases. A new reporting checklist published the same month explains why such claims are hard to compare.